Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis-Reference-Cited by-同舟云学术

Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis

Published:2022-05-04 Issue:4 Volume:56 Page:614-624
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Taxonera Carlos¹²^ORCID,Fernández‐Aceñero María Jesús³,Olivares David¹²,Calvo Marta⁴,Casis Begoña⁵,Bermejo Fernando⁶,López Serrano Pilar⁷,Iborra Marisa⁸^ORCID,Mesonero Francisco⁹^ORCID,Boscá Watts Maia¹⁰,Díaz del Arco Cristina³^ORCID,Vera Isabel⁴,Olivares Sonsoles⁵,Algaba Alicia⁶,Alba Cristina¹²

Affiliation:

1. Inflammatory Bowel Disease Unit, Department of Gastroenterology Hospital Clínico San Carlos and Instituto de Investigación del Hospital Clínico San Carlos [IdISSC] Madrid Spain

2. Instituto de Investigación del Hospital Clínico San Carlos [IdISSC] Madrid Spain

3. Department of Pathology Hospital Clínico San Carlos Madrid Spain

4. Department of Gastroenterology Hospital Universitario Puerta de Hierro Madrid Spain

5. Department of Gastroenterology Hospital Universitario 12 de Octubre Madrid Spain

6. Department of Gastroenterology Hospital Universitario Fuenlabrada Madrid Spain

7. Department of Gastroenterology Hospital Universitario Fundación Alcorcón Madrid Spain

8. Department of Gastroenterology Hospital Universitario La Fe Valencia Spain

9. Department of Gastroenterology Hospital Universitario Ramón y Cajal Madrid Spain

10. Department of Gastroenterology, Hospital Clínico Universitario de Valencia Valencia Spain

Funder

Merck Sharp and Dohme

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.16964

Reference33 articles.

1. Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

2. Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis

3. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

4. Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study

5. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study;Alimentary Pharmacology & Therapeutics;2023-02-27

2. Therapeutic drug monitoring of TNFα inhibitors: a spotlight on novel techniques and assays;Expert Opinion on Drug Metabolism & Toxicology;2022-10-03

3. Editorial: golimumab thresholds to achieve stringent medium‐ and long‐term therapeutic outcomes in patients with ulcerative colitis—Author’s reply;Alimentary Pharmacology & Therapeutics;2022-07-25

4. Editorial: golimumab thresholds to achieve stringent medium‐ and long‐term therapeutic outcomes in patients with ulcerative colitis;Alimentary Pharmacology & Therapeutics;2022-07-25